BATM19 Jan 2021 13:59
Bought into these this morning below courtesy of Investors Chronicle
BATM firing on all cylinders
Covid-19 antigen test delivered to European private and government customers.
New technology rapidly diagnoses infections using DNA or RNA.
BATM Advanced Communications (BVC:100p), a provider of medical laboratory systems, diagnostic kits, cyber security and network solutions, has made three important announcements.
Firstly, its COVID-19 tests have been proved effective in accurately detecting all variants of the virus, including the latest mutations. BATM’s antigen test has 4+1 gene discovery capability, including the S-protein, compared with a market standard of one to three gene discovery. This enables it to provide more accurate results, reducing the risk of false positives and false negatives. It is being delivered to several private and government customers in Europe and other geographies.
Secondly, associate company Ador Diagnostics has developed a new innovative technology that can provide sample-to-answer diagnostics of bacterial, viral or fungal infections using DNA or RNA sampling in 15-20 minutes compared with 60-90 minutes for polymerase chain reaction (PCR). Ador’s NATlab molecular diagnostic bench-top analyser can analyse several pathogens (currently up to 400) at the same time, thus detecting all the possible pathogens associated with diseases such as meningitis, sepsis and respiratory diseases.
By accurately detecting the right strain of a disease, the correct treatment can be started immediately – something that is not possible with PCR methods. Several universities and hospitals in the UK, Europe, Israel and the USA are co-operating with Ador and in-hospital trials will commence in the first half. Demand is likely to be strong given that the speed and accuracy of identifying an infection is vital in providing the correct treatment and containing potential disease outbreaks.
Thirdly, BATM is selling its non-core NG Soft software subsidiary for US$33m (£24.5m) to unlock value for shareholders. The group will use the proceeds to accelerate growth in its core bio-medical, cyber security and network function virtualisation technology business, the latter is playing a critical role in the range of 5G services telecom operators can offer.
Sign In
Follow the stocks
